目的 探討納洛酮聯(lián)合依達(dá)拉奉治療腦血管疾病的療效及其機制。方法 將180例缺血性腦血管疾病患者隨機分為兩組，每組各90例，對照組給予依達(dá)拉奉注射液30 mg靜脈滴注，每日2次，研究組在對照組基礎(chǔ)上給予鹽酸納洛酮注射液2 mg靜脈滴注，每日2次。兩組均連用14 d。分別在治療前、治療后檢測血清丙二醛（MDA）、超氧化物岐化酶（SOD）濃度以及血液流變學(xué)指標(biāo)。比較兩組的臨床療效和不良反應(yīng)。結(jié)果 治療后，兩組血清MDA濃度均較治療前降低，SOD濃度均較治療前升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且研究組MDA濃度明顯低于對照組，SOD濃度明顯高于對照組，組間比較差異有統(tǒng)計學(xué)意義（P<0.05）。研究組治療后血液流變學(xué)指標(biāo)改善情況明顯優(yōu)于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。研究組總有效率94.4%，明顯高于對照組83.3%，差異有統(tǒng)計學(xué)意義（P<0.05）。兩組均無明顯不良反應(yīng)。結(jié)論 納洛酮聯(lián)合依達(dá)拉奉治療腦血管疾病能增進療效，其機制可能與提高SOD，降低MDA，改善腦組織供血有關(guān)。

Objective To investigate the effect and mechanism of edaravone combined with naloxone in treatment of cerebral vascular disease. Methods 180 patients with ischemic cerebrovascular disease were randomly divided into two groups with 90cases in each group, and the control group were treated with Edaravone, and the study group were treated with Edaravone combined with Naloxone. The serum malondialdehyde (MDA), superoxide dismutase (SOD) concentration and blood rheology indexs before and 14d after treatment of were detected, and clinical efficacy and adverse reactions were compared between the two groups. Results The serum MDA concentration 14d after treatment of the study group was significantly lower than that of the control group (P < 0.05), and the SOD concentration was significantly higher than that of control group (P < 0.05). The blood rheology indexs 14 d after treatment of the study group were significantly improved than those of the control group (P < 0.05). The total effective rate of the study group with 94.4% was significantly higher than that of the control group with 83.4% (P < 0.05). There were no obvious adverse reaction in the two groups. Conclusions Edaravone combined with naloxone in treatment of cerebral vascular disease can enhance the therapeutic effect, and the mechanism may be associated with increased SOD, reduced MDA, and improved blood supply to the brain.